CEDAR KNOLLS, N.J., May 4,
2020 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or
"the Company") (NASDAQ: MYOS), an advanced nutrition company and
the owner of Fortetropin®, a
proprietary bioactive composition that helps build lean muscle,
will announce financial results for the first quarter of 2020 on
Friday, May 8, 2020 at 11:30 AM ET.
The Company will host a conference call on Friday, May 8, 2020 at 11:30 AM ET, at which time MYOS' Chief Executive
Officer Joseph Mannello will provide
commentary on earnings results for the first quarter and provide an
update on the business.
Conference Call
Details:
|
|
|
Call
Date/Time:
|
Friday, May 8,
2020 at 11:30 AM ET
|
|
|
Call
Title:
|
MYOS RENS
Technology First Quarter 2020 Results Conference
Call
|
|
|
Dial
In:
|
877-407-9120
from the U.S.; international callers may telephone 412-902-1009
approximately 15 minutes before the call.
|
|
|
|
A digital replay
will be available by telephone approximately two hours after the
completion of the call until May 22, 2020 and may be accessed by
dialing 877-660-6853 from the U.S., or 201-612-7415 for
international callers, using the Conference ID#
13703019.
|
This call will be simultaneously webcast and will be available
on the MYOS website, www.myosrens.com, in the "Investor Relations"
section. An archive of the webcast will be available at the same
web address for two weeks following the call.
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based advanced
nutrition company that develops and markets products that improve
muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg
yolk-based product manufactured via a proprietary process to retain
and optimize its biological activity. Fortetropin has been
clinically shown to increase muscle size, lean body mass and reduce
muscle atrophy. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.myosrens.com.
Forward-Looking Statements
Any statements in this release that are not historical facts
are forward-looking statements. Actual results may differ
materially from those projected or implied in any forward-looking
statements. Such statements involve risks and uncertainties,
including but not limited to those relating to product and customer
demand, market acceptance of our products, the ability to create
new products through research and development, the successful
results of strategic initiatives, the success of our products,
including Yolked®,
Physician Muscle Health Formula®, MYOS
Canine Muscle
Formula®, Qurr®
and MYOS Enteral
Nutrition Formula™, the success of our
research and development, the results of the clinical evaluation
of Fortetropin® and its
effects, the ability to enter into new partnership opportunities
and the success of our existing partnerships, the ability to
generate revenue and cash flow from sales of our products, the
ability to increase our revenue and gross profit margins, the
ability to achieve a sustainable, profitable business, the effect
of economic conditions, the ability to protect our intellectual
property rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock
Market, risks in product development, our ability to raise capital
to fund continuing operations, the adverse impact of the
coronavirus on the economy and our business, and other
factors discussed from time to time in our filings with the
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statement for events or
circumstances after the date on which such statement is made except
as required by law.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-announces-the-date-for-first-quarter-2020-conference-call-and-webcast-301051382.html
SOURCE MYOS RENS Technology